Regeneron Pharmaceuticals, Inc.
 |
|
| Public | |
| Traded as |
|
| Industry | Pharmaceuticals; Biotech |
| Founded | 1988 |
| Headquarters | Tarrytown, New York, US (Headquarters) |
|
Area served
|
Worldwide |
|
Key people
|
|
| Revenue |
 $4.1 billion |
|
$1.4 billion |
|
| Total assets |
$5.6 billion |
| Owner | Sanofi (22.6%) |
| Website | www |
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
On March 26, 2012 Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810. REGN2810 was later named cemiplimab.
ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
EYLEA (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011. EYLEA developed to treat a common cause of blindness in the elderly.
ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.
...
Wikipedia